

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

Date: 10 September, 2020

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

Dear Sir / Madam,

SUB: DISCLOSURE OF MATERIAL IMPACT OF COVID-19 PANDEMIC ON THE COMPANY.

REF.: SEBI CIRCULAR NO. SEBI/HO/CFD/CMD1/CIR/P/2020/84 DATED 20TH MAY, 2020

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated 20th May, 2020, please find enclosed herewith as Annexure-A, disclosure of Impact of COVID-19 pandemic on the Company.

Kindly take the same on record.

Thanking You.

Yours faithfully,
For Vaishali Pharma Limited


Atul Vasani
Managing Director



Encl.: As above

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

Annexure – A

Additional Disclosure of material impact of COVID-19 pandemic on the Company.

In the last month of Financial Year 2020, the COVID-19 pandemic developed rapidly into a global crisis, compelling governments to enforce lock-down of all economic activities.

A. Impact of the COVID-19 pandemic on the business;

Almost 5 month's revenue have been affected i.e 2 Months of F.Y. 2019-20 and 3 Months of Current year.

B. Ability to maintain operations including the factories/units/office spaces functioning and closed down;

The Company has adhered to all recommended precautions/guidelines in its operations, which includes sanitization and hygiene, providing work from home facility to all employees, maximizing audio & video-conferencing and minimizing contact, closing employee travel and following all government directions on the subject.

C. Schedule, if any, for restarting the operations;

The Company had partially resumed operations gradually, as per the permission granted by the respective Local Authorities with less number of workmen and employees after initiating all necessary safety measures.

The offices of the Company had also resumed with limited attendance gradually from 8th June, 2020, in line with the guidelines issued by the Central / State government.

D. Steps taken to ensure smooth functioning of operations;

We have taken the following steps to ensure smooth functioning of operations:

- We keep social distancing in office
- We Sanitize our Office on regular basis
- All office Staff is advice to take proper precautions of their health
- We take temperature and Oxygen levels of each and every person who enters the premises
- Proper ventilation facility in the premises.
- We follow all the Government norms to control Covid 19

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

E. Estimation of the future impact of COVID-19 on its operations;

Due to unpredictable situation evolving on account of pandemic, it is difficult to estimate the definite impact of COVID-19 on the operations of the Company beyond Q1 of the FY 2020-21.

F. Details of impact of COVID-19 on the Company;

Capital and financial resources	Financial resources would be stretched to certain extent. However, Company will be able to meet all its obligations. Additional funding required will be provide by the Bank and other Financial Institutions
Profitability	Net profitability got reduced due to increase in Administrative and other expenses.
Liquidity Position	It will normalize in three to four months.
Ability to service debt and other financing arrangements	Company will be able to meet all its debts etc. as it comes up.
Assets	Company will not procure any Capital Assets.
Internal financial reporting and control	It will normalize in two to three months.
Supply chain	It will normalize in two to three months.
Demand for its products/services	It will continue at much slower pace.

Existing contracts/agreements where non-fulfillment of the obligations by any party will have significant impact on the listed entity's business:

We don't expect this to have significant impact on the business of the Company.

G. Other relevant material updates about the listed entity's business;

Apart from above, the Company have no other material updates to disclose.
